Healthcare Mega-Deals 2024-2026: The Transactions Every Candidate Must Know

Introduction

Healthcare M&A is in its most active stretch in years, and the defining feature is deal size. J.P. Morgan's 2025 biopharma deal review counted 129 acquisitions worth $138 billion, nine of them above $5 billion, and GlobalData's year-end tally put total pharma M&A at $179.6 billion through mid-December 2025, up 31% on 2024. Across all health industries, PwC found disclosed deal value rose 46% even as deal count fell about 6%: fewer transactions, much bigger checks. Then 2026 went further. IQVIA's mid-year review tallied $130 billion across 42 biopharma acquisitions in the first half alone, an average of $3.1 billion per deal and almost the full-year 2025 total on its count.

The activity is not random. It is driven by a convergent set of structural forces: the $236 billion patent cliff, the GLP-1 revolution reshaping metabolic disease, renewed sponsor appetite for large-cap medtech, and acquirers with clean balance sheets and urgent pipeline gaps. Interviewers at healthcare-focused banks will ask "what deal are you following?" and expect the strategic rationale, not just awareness that a transaction occurred. This article works through the most important healthcare transactions of 2024-2026, plus the 2023 Pfizer/Seagen deal that set the tone for the cycle, organized by the strategic theme that drove each one.

The largest driver of biopharma M&A is the impending loss of exclusivity for blockbuster drugs. Pharma companies facing patent cliffs must acquire pipeline assets to replace revenue they know they will lose. These deals are characterized by urgency (the buyer's timeline is set by LOE dates), premium pricing (asset scarcity drives competition among multiple potential acquirers), and contingent consideration (bridging valuation gaps with CVRs and milestones).

Pfizer / Seagen ($43 Billion, 2023)

The landmark transaction of the current M&A cycle, announced in March 2023 and closed that December. Pfizer acquired Seagen, the leading antibody-drug conjugate company, for $229 per share in cash, an enterprise value of about $43 billion. The strategic rationale was straightforward: Pfizer faced falling COVID franchise revenue and an approaching LOE wave for drugs such as Ibrance and Eliquis, and needed a transformative oncology platform. Seagen brought four approved medicines, three of them ADCs (Adcetris, Padcev, Tivdak) plus the HER2-targeted small molecule Tukysa, and Pfizer's deal announcement put Seagen's expected 2023 revenue at about $2.2 billion. Pfizer projected more than $10 billion of risk-adjusted revenue from the business by 2030. Its ADC technology platform added a pipeline of next-generation programs on top.

J&J / Intra-Cellular Therapies ($14.6 Billion, 2025)

Johnson & Johnson agreed in January 2025 to acquire Intra-Cellular Therapies to strengthen its neuroscience portfolio. Intra-Cellular's lead product, Caplyta (lumateperone), was approved for schizophrenia and bipolar depression and was generating rapidly growing revenue with significant expansion potential. The deal reflected a broader 2025 trend: in GlobalData's count of US-focused deals, CNS/neurology overtook oncology as the largest therapeutic area by M&A value, capturing $30.7 billion versus $23.5 billion for oncology.

The CNS Renaissance in Biopharma M&A

After years in which oncology was usually the single largest therapeutic area in biopharma M&A, 2025 marked a turning point as neuroscience emerged as the largest therapeutic area by acquisition value. This shift was driven by multiple factors: new scientific understanding of neurological disease mechanisms (particularly in schizophrenia, depression, and neurodegeneration), the approval of breakthrough therapies that validated new targets, and the recognition by large pharma companies that CNS represents one of the last large therapeutic categories where significant unmet need exists and competition is relatively limited. J&J/Intra-Cellular was the largest single manifestation of this trend, with AbbVie/Cerevel (announced in late 2023) an early signal of it. Treat it as a broadening of M&A demand rather than a permanent rotation: in the first half of 2026, oncology reclaimed 41% of biopharma M&A value on IQVIA's count, with neurology at 9%.

Merck / Cidara Therapeutics ($9.2 Billion, 2025)

Merck's November 2025 acquisition of Cidara Therapeutics for approximately $9.2 billion targeted CD388, a late-stage, long-acting antiviral designed to prevent influenza with a single dose per season. The deal highlighted Merck's diversification strategy beyond oncology (where Keytruda's LOE exposure creates $29 billion+ in revenue at risk) into infectious disease, a therapeutic area with large patient populations and favorable reimbursement dynamics. It also showed acquirers paying blockbuster premiums in areas underinvested during oncology's long dominance: infectious disease, respiratory, and immunology assets have re-rated as buyers diversify beyond a crowded oncology landscape.

Novartis / Avidity Biosciences ($12 Billion, 2025)

Novartis acquired RNA therapeutics developer Avidity Biosciences for approximately $12 billion, securing Avidity's antibody-oligonucleotide conjugate (AOC) platform. The deal reflected the growing conviction that RNA-based therapeutics represent the next major modality platform after antibodies and ADCs. Avidity's technology enables targeted delivery of RNA therapeutics to muscle tissue, with lead programs in myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. For Novartis, the acquisition filled a gap in its modality portfolio and positioned it in the emerging RNA therapeutics space alongside Alnylam (RNAi) and Ionis (antisense oligonucleotides).

Sanofi / Blueprint Medicines ($9.1 Billion, 2025)

Sanofi's acquisition of Blueprint Medicines for $9.1 billion upfront (up to about $9.5 billion with a CVR) added a precision oncology and allergy platform anchored by Ayvakit (avapritinib) for systemic mastocytosis. The deal was notable because Blueprint's commercial-stage product provided immediate revenue contribution while its pipeline offered multiple expansion opportunities. It was one of nine 2025 biopharma acquisitions above $5 billion in J.P. Morgan's count, alongside J&J/Intra-Cellular, Novartis/Avidity, Merck/Verona, Pfizer/Metsera and Merck/Cidara.

AbbVie / Cerevel Therapeutics ($8.7 Billion, 2024)

AbbVie's $8.7 billion acquisition of Cerevel (announced December 2023, closed August 2024) is the cycle's clearest lesson in binary clinical risk. The deal rested on two pillars: emraclidine, a muscarinic receptor agonist for schizophrenia, and tavapadon, a Phase 3 candidate for Parkinson's disease. In November 2024, emraclidine missed its primary endpoint in two Phase 2 EMPOWER trials and AbbVie wrote down billions of the purchase price. Tavapadon then rescued much of the thesis: the FDA approved it as Juvmo in September 2026, the first marketed product from the deal. The lesson for anyone valuing a pipeline acquisition: premiums paid for mid-stage assets carry real failure risk, and a deal built on more than one late-stage asset can survive the loss of one.

The GLP-1 revolution has triggered a wave of M&A as companies race to establish positions in the obesity and cardiometabolic markets.

Pfizer / Metsera ($10 Billion, 2025)

Pfizer acquired Metsera, a clinical-stage biotech developing long-acting GLP-1 receptor agonists, for up to $10 billion after a bidding war with Novo Nordisk in November 2025. Pfizer's opening September offer of $4.9 billion upfront ended at $65.60 per share in cash plus a CVR worth up to $20.65 per share. The deal highlighted the strategic urgency in GLP-1: Pfizer had discontinued its internal oral GLP-1 candidate (danuglipron) in April 2025 after a liver-safety signal, and Metsera's differentiated delivery system (designed for monthly or less frequent dosing) offered a potentially best-in-class profile that could differentiate Pfizer in a market projected to reach $130-200 billion+.

Novo Nordisk / Akero Therapeutics ($5.2 Billion, 2025)

Novo Nordisk's acquisition of Akero for up to $5.2 billion ($54 per share in cash plus a CVR of up to $6) expanded its metabolic disease portfolio beyond GLP-1 into MASH (metabolic dysfunction-associated steatohepatitis), a liver disease with significant unmet need and a large potential market. Akero's lead asset, efruxifermin, is an FGF21 analog in Phase 3. The deal showed Novo's strategy of leveraging its metabolic disease commercial infrastructure to build a broader cardiometabolic franchise.

Novo Holdings / Catalent ($16.5 Billion, 2024)

The Novo/Catalent transaction deserves its own discussion because it was not a typical pipeline acquisition. Novo Holdings (the investment arm of the foundation that controls Novo Nordisk) acquired Catalent, a diversified CDMO, for $16.5 billion, while Novo Nordisk agreed to buy three of Catalent's fill-finish sites from Novo Holdings for $11 billion to expand semaglutide production. This was a vertical integration play driven by manufacturing capacity constraints: Novo Nordisk was losing billions in potential revenue because it could not produce enough semaglutide to meet demand. The deal illustrates how modality-specific capacity constraints can drive CDMO valuations to strategic premiums far above standalone financial analysis.

J&J / Shockwave Medical ($13.1 Billion, 2024)

J&J's acquisition of Shockwave Medical for $13.1 billion secured intravascular lithotripsy (IVL) technology, which uses sonic pressure waves to treat calcified arterial disease. The strategic rationale was both offensive (adding a high-growth device category to J&J's cardiovascular portfolio) and defensive (preventing competitors from acquiring the technology). Shockwave's IVL platform had already moved beyond peripheral arteries into the larger coronary market (its US coronary approval came in 2021), creating a revenue growth trajectory that justified the premium valuation.

Intravascular Lithotripsy (IVL)

A catheter-based technology that uses sonic pressure waves (similar to kidney stone lithotripsy) to crack calcified plaque in arteries, restoring vessel compliance and enabling stent deployment in heavily calcified lesions that are difficult to treat with conventional balloon angioplasty. Shockwave Medical pioneered this approach and was the sole commercial provider at the time of J&J's acquisition, creating a competitive moat that justified the $13.1 billion price tag.

Abbott / Exact Sciences ($23 Billion, 2025)

Abbott agreed in November 2025 to acquire molecular diagnostics company Exact Sciences for $105 per share in cash, which Abbott's deal announcement valued at about $21 billion of equity and $23 billion of enterprise value, and closed the deal in March 2026. It ranks among the largest diagnostics deals in history. Exact Sciences' Cologuard franchise (non-invasive, at-home colorectal cancer screening) is a high-growth testing business with a large unscreened eligible population, widened when US screening guidelines lowered the recommended starting age to 45 in 2021. Exact expected more than $3 billion of 2025 revenue, growing in the high teens. For Abbott, the deal adds a leading position in cancer screening and precision oncology to its existing core lab and point-of-care testing platforms. The strategic logic follows the tools/diagnostics playbook: acquiring a consumables-driven, recurring-revenue business with spec-in protection and long-term growth visibility.

Blackstone-TPG / Hologic ($18.3 Billion, 2025)

In one of the largest PE-led healthcare transactions of the cycle, Blackstone and TPG jointly agreed in October 2025 to acquire women's health company Hologic for up to $18.3 billion: $76 per share in cash plus a CVR worth up to $3, tied to Breast Health revenue goals. The deal closed in April 2026 with significant minority investments from ADIA and GIC. Hologic's portfolio spans breast and cervical cancer screening, surgical products, and diagnostics. The deal is significant for multiple reasons: it demonstrates PE appetite for large-cap medtech acquisitions (not just healthcare services), the consortium structure (two sponsors plus sovereign co-investors) reflects a deal size beyond any single firm's typical check, and Hologic's recurring revenue profile from diagnostic consumables and surgical instruments provides the predictable cash flows PE firms seek.

Forecasts of a blockbuster 2026 are being borne out, and the year's deals are larger and more concentrated in near-commercial assets than in any recent cycle. The third quarter cooled without breaking that pace: William Blair's Q3 2026 recap counts about $39 billion of announced US biopharma M&A across 15 deals, down from a record second quarter, yet 40 deals above $1 billion year to date already beat the prior full-year record, and acquisitions of private biotechs made up most of the quarter's activity. Several dynamics stand out.

Mega-deals across the buyer universe. IQVIA counts three biopharma acquisitions above $10 billion in the first half of 2026: Sun Pharma/Organon ($11.8 billion), AbbVie/Apogee ($10.9 billion, for a long-acting IL-13 antibody in atopic dermatitis) and GSK/Nuvalent ($10.6 billion), plus six more between $5 billion and $10 billion, including Gilead/Arcellx and Eli Lilly/Centessa. In July, Vertex agreed to buy Crinetics for $85 per share, about $10 billion and its largest deal ever, adding the approved oral acromegaly drug Palsonify and a Phase 3 asset in congenital adrenal hyperplasia. Eli Lilly has been the year's most frequent acquirer, recycling GLP-1 cash flow into deals such as Centessa ($7.8 billion) and Kelonia ($7 billion).

GSK/Nuvalent. In June 2026, GSK agreed to acquire Nuvalent for $10.6 billion, its largest acquisition in over a decade and the first major deal under CEO Luke Miels. The all-cash tender offer ($124 per share, a 40% premium) secured two potential best-in-class lung cancer inhibitors targeting ROS1 and ALK, and closed in July. The de-risking came fast: the FDA approved zidesamtinib as Jideytro ahead of its September target date, with a decision on neladalkib due in late November 2026. It exemplifies the patent-cliff-driven rush to rebuild oncology pipelines with validated, near-commercial assets.

Revolution Medicines. Revolution has been the year's most closely watched takeover target that did not sell. Merck held talks to acquire it for a reported $28-32 billion in early 2026, which would have been the largest biotech acquisition since Pfizer/Seagen, but walked away over price in late January, and AbbVie publicly denied involvement. The asset only strengthened afterward. In the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, daraxonrasib delivered median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40), and Revolution raised about $2.2 billion in April. On August 26 the FDA approved daraxonrasib as Rasonque, about six and a half months ahead of its goal date under the Commissioner's National Priority Voucher pilot, the first RAS inhibitor approved for pancreatic cancer. Revolution is now a commercial-stage company with a marketed drug, so a bidder would be paying for launch revenue rather than trial data. That raises the price of any future bid further rather than ending the takeover story.

Continued patent cliff urgency. With $236 billion in branded drug revenue facing LOE through 2030, and roughly 190 drugs (including 69 blockbusters) losing market exclusivity during this period, the acquisition imperative only intensifies. Buyers are paying for near-commercial certainty: GSK bought two filed drugs and Vertex an approved one, rather than early platforms.

PE services activity. Beyond biopharma, sponsor behavior in healthcare services has shifted. PwC reports that PE sponsors are moving away from reimbursement-dependent businesses toward AI-enabled software and services, while platform and add-on strategies continue in fragmented outpatient niches. Healthcare provider M&A was muted in 2025, with dealmakers shifting toward mid-market and distress-driven transactions, reflecting tight margins, labor pressures, and heightened FTC antitrust scrutiny. The contrast between booming biopharma M&A and notably more cautious services dealmaking is a dynamic that candidates should be prepared to discuss in interviews.

Medtech and tools consolidation. The predicted medtech wave has arrived. Abbott/Exact Sciences and Blackstone-TPG/Hologic both closed in the spring of 2026, and in January Boston Scientific agreed to buy Penumbra for $14.5 billion in cash and stock, its largest deal in two decades, adding thrombectomy devices for pulmonary embolism, stroke and deep vein thrombosis. In February, Danaher agreed to buy Masimo for $180 per share, an enterprise value of about $9.9 billion and its largest deal since Cytiva in 2020, bringing pulse oximetry and patient monitoring into its diagnostics segment; the deal closed in June. PwC's first-half medtech review names Penumbra and Masimo as the deals that led the period's value. In life sciences tools, Merck KGaA agreed in June to acquire Bio-Techne at an enterprise value of about $11.3 billion. Large medtech companies face their own version of the growth challenge: maturing product lines, pricing pressure from hospital GPOs, and competition from emerging technology platforms. Acquiring high-growth categories such as thrombectomy, diagnostics and robotic surgery offers a path to re-accelerate organic growth.

The next article covers the GLP-1 revolution and how obesity drugs are reshaping healthcare investment banking across every sub-sector.